Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY26 results · Oct–Dec 2025
Marksans Pharma reported revenue from operations of ₹754.43 crore (up 10.6% from Q3 FY25) and net profit of ₹113.69 crore (up 8.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 754.43 | 681.85 | +10.6% | 720.41 | +4.7% |
| Other income | 20.14 | 27.85 | −27.7% | 21.57 | −6.6% |
| Total income | 774.57 | 709.70 | +9.1% | 741.98 | +4.4% |
| Profit before tax | 150.62 | 143.26 | +5.1% | 133.33 | +13.0% |
| Net profit for the period | 113.69 | 105.07 | +8.2% | 99.14 | +14.7% |
| Attributable to shareholders of the company | 113.20 | 104.56 | +8.3% | 98.25 | +15.2% |
| EPS, basic (₹) | 2.50 | 2.31 | +8.4% | 2.17 | +15.2% |
| Net margin (%) | 15.1 | 15.4 | 13.8 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 339.73 | 311.87 | +8.9% | 320.44 | +6.0% |
| Other income | 15.86 | 22.51 | −29.5% | 58.19 | −72.7% |
| Total income | 355.59 | 334.37 | +6.3% | 378.63 | −6.1% |
| Profit before tax | 82.12 | 74.72 | +9.9% | 121.49 | −32.4% |
| Net profit for the period | 60.91 | 55.46 | +9.8% | 99.81 | −39.0% |
| EPS, basic (₹) | 1.34 | 1.22 | +9.8% | 2.20 | −39.1% |
| Net margin (%) | 17.9 | 17.8 | 31.1 |
Consolidated
- Filed with BSE
- 05 Feb 2026, 16:45 IST
- Board meeting
- 05 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2026, 16:45 IST
- Board meeting
- 05 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE